Startup Raises $250 Million to Extend Dogs’ Healthy Lifespans

A Big Bet on Longer Lives for Dogs
A canine health startup called Loyal has raised more than $250 million to develop drugs designed to help dogs live longer, healthier lives. The company’s lead product, LOY-002, is a daily, beef-flavored prescription pill aimed at extending the healthy lifespan of senior dogs. Loyal recently announced an additional $100 million in Series C funding as it moves closer to seeking FDA approval for the drug.

How the Drug Works
LOY-002 is designed to mimic some of the effects of calorie restriction, a method linked in research to improved metabolic health and longevity, without forcing pet owners to reduce their dogs’ food intake. The goal is to address age-related metabolic decline while preserving normal appetite and behavior — a key part of the human-dog bond. Loyal says the drug is currently in clinical trials and could become the first FDA-approved lifespan-extension medication for any species.

Why Dogs First?
Founder and CEO Celine Halioua says dogs offer a unique opportunity for longevity research. Because dogs share many biological similarities with humans but have much shorter lifespans, researchers can study the effects of aging interventions more quickly. Loyal is running what it calls the largest animal health clinical trial to date, enrolling roughly 1,300 dogs across dozens of veterinary clinics to test whether LOY-002 can add at least one healthy year to a dog’s life.

What Comes Next
If approved, LOY-002 would initially be labeled for senior dogs over a certain age and weight, with monthly costs expected to vary by size. Loyal is also developing two additional longevity treatments aimed at different canine populations, including larger breeds that typically age faster.

Why It Matters
Beyond the promise for pets, researchers say breakthroughs in canine longevity could provide valuable insights into human aging. For dog owners, the appeal is simple: more healthy time with the companions they love.